Bristol-Myers Gets European Approval for Revlimid Combination for Follicular Lymphoma
December 20 2019 - 7:47AM
Dow Jones News
By Michael Dabaie
Bristol-Myers Squibb Co. (BMY) said the European Commission
approved a new indication for Revlimid, in combination with
rituximab (anti-CD20 antibody), for adult patients with previously
treated follicular lymphoma.
FL is a subtype of indolent, but incurable, non-Hodgkin lymphoma
which is associated with immune system dysfunction.
The approval was based primarily on results from the phase 3
Augment study, which evaluated the combination versus rituximab
plus placebo. In the study, treatment with the combination
demonstrated a statistically significant improvement in the primary
endpoint of median progression-free survival, Bristol-Myers
said.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
December 20, 2019 07:32 ET (12:32 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bristol Myers Squibb (NYSE:BMY)
Historical Stock Chart
From Apr 2023 to Apr 2024
